Virgin Herbert 4
4 · Vir Biotechnology, Inc. · Filed Feb 24, 2022
Insider Transaction Report
Form 4
Virgin Herbert
EVP, Research & CSO
Transactions
- Award
Common Stock
2022-02-22+70,000→ 175,407 total - Exercise/Conversion
Common Stock
2022-02-22$1.53/sh+1,375$2,104→ 176,782 total - Sale
Common Stock
2022-02-22$30.00/sh−1,375$41,250→ 175,407 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-02-22−1,375→ 219,505 totalExercise: $1.53Exp: 2028-01-26→ Common Stock (1,375 underlying) - Award
Stock Option (Right to Buy)
2022-02-22+70,000→ 70,000 totalExercise: $29.48Exp: 2032-02-21→ Common Stock (70,000 underlying)
Footnotes (4)
- [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
- [F3]The option is fully vested and exercisable.
- [F4]25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.